Treatment of MF-associated Anemia

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: April 23, 2021
Expiration Date: April 23, 2022

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, Dr. Srdan Verstovsek will discuss management of myelofibrosis-associated anemia. He will provide guidance on thresholds for red blood cell transfusion, criteria for selecting anemia therapy, and current and emerging treatment options for managing anemia, including erythropoiesis-stimulating agents (ESAs), anabolic steroids, corticosteroids, immunomodulatory agents, Janus kinase (JAK) inhibitors, anti-hemojuvelin antibodies, ALK2 receptor inhibitors, and luspatercept.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myeloproliferative neoplasms.

Learning Objective

Upon completion of this educational activity, participants should be able to:

  • Describe the current and emerging strategies under investigation to improve MF-associated anemia


Treatment of MF-associated Anemia - Srdan Verstovsek, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through April 23, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Srdan Verstovsek, MD, PhD
United Energy Resources, Inc.
Professor of Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas

Dr. Srdan Verstovsek received his medical and doctoral degrees at the University of Zagreb in Croatia. He completed his postdoctoral research fellowship in cancer biology at Roswell Park Cancer Institute, his residency in internal medicine at the State University of New York, both located in Buffalo, New York, and his fellowship in oncology and hematology at The University of Texas MD Anderson Cancer Center, Houston, Texas. He is the United Energy Resources, Inc., Professor of Medicine and a hematologist-oncologist at MD Anderson Cancer Center.

Dr. Verstovsek is a global leader in myeloproliferative neoplasms (MPN) and the founder/director of the largest MPN Clinical Research Center worldwide. He is co-founder/executive committee member of the International Working Group for Myelofibrosis Treatment and Research. Dr. Verstovsek has achieved international acclaim for his leadership in developing landmark MPN therapeutics and led more than 60 early/advanced phase clinical trials of novel MPN drugs, including ruxolitinib, the only FDA-approved medication for myelofibrosis, and second-line treatment for polycythemia vera. In addition, he is leading pivotal phase 3 trials for several promising myelofibrosis medications. Dr. Verstovsek has published numerous books, chapters, peer-reviewed articles, and reviews in the New England Journal of Medicine, Blood, Leukemia, and Lancet, among others. His contributions in MPN have been globally recognized with numerous invitations as an expert speaker/educator at national and international conferences. Dr. Verstovsek regularly engages at multiple levels with MPN patients’ advocacy groups/societies.


MediCom Worldwide, Inc. CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .25 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-21-022-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Srdan Verstovsek has received grant support related to research activities from AbbVie Inc., Blueprint Medicines, Celgene Corporation, Constellation Pharmaceuticals, CTI BioPharma Corp., F. Hoffmann-La Roche Ltd, Gilead, NS Pharma, Inc., Incyte Corporation, Italfarmaco, Kartos Therapeutics, Inc., Novartis AG, NS Pharma, Inc., PharmaEssentia Corporation, Promedior, Inc., Protagonist Therapeutics, Inc., and Sierra Oncology, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Wayne Kuznar, Medical Writer, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.

©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.